CSI Market
Sign In | Register

Neuroone Medical Technologies (NMTC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NMTC Annual Cash Flow →
A period-by-period view of cash flow from Neuroone Medical Technologies to Mar 31 2025 helps clarify how Mar 31 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
6 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-2.38
Depreciation & amortization0.13
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.36
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.70
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.21
Net Income Loss During The Development Stage-
Related Party Costs-
Accrued Payables-
Disposal Group Of Equity From Discontinued Operations-
Increase Decrease In Assets From Discontinued Operations-
Forgiveness Of Share Subscription Agreement For Founders Shares-
Revaluation Of Premium Debt Conversion Derivative-
Forgiveness Of Subscription-
Lease Liability Principal Payment Deferral Amount-
Allocated Share Based Compensation-
Fair Value Change Of Convertible Notes-
Revaluation Of Premium Conversion Derivatives And Warrant Liability-
Noncash Lease Expense0.06
Debt And Equity Facility Costs Reclassed To Financing Activities-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.63
Increase (Decrease) in Accounts Payable-0.06
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.59
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.14
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-4.44
Investing Activities
Capital Expenditures-0.08
Sale of Capital Items0.00
Payments to Acquire Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Collection of Advance to Affiliate0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.08
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.82
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.06
Notes Payable-
Sale Of Common Stock-
Proceeds From Issuance Of Warrants Associated With Convertible Promissory Notes-
Proceeds From Issuance Of Warrants With Private Placement-
Payments Related To Warrant Issuance Costs-
Proceeds From Unsecured Loan-
Repayment Of Unsecured Loans-
Issuance Costs Related To Private Placements-
Issuance Costs Related To Convertible Notes-
Proceeds From Issuance Of Common Stock In Connection With Private Placement-
Proceeds From Advance Related To Future Financing-
Issuance Costs In Connection With Private Placements-
Proceeds From Paycheck Protection Program-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.76
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-4.52
Total Cash Flow-3.77
4 historic quarters locked

Sign in to unlock the full Neuroone Medical Technologies cash flow history.

Sign In Create Free Account

About Neuroone Medical Technologies Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-088724

Figures are derived from filed reports and may be restated. Historical data is subject to revision.